Jasper Therapeutics Stock
Jasper Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jeetinder Singh Mahal
- Employees
- 22
- Market cap
- $16 M
- IPO
- 10/01/2020
- Web
- jaspertx.com
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117…
Jasper Therapeutics stock: price history
1D
-9.8%
1W
-15.8%
1M
-17.4%
6M
-53.0%
YTD
-73.8%
1Y
-80.6%
2Y
-97.4%
5Y
-99.7%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~34% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Jasper Therapeutics
Analyst assessment of Jasper Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$2.50
MEDIAN
US$2.50
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
8
BUY
5
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 15/05/2026
Jasper Therapeutics stock metrics
P/E
-0.3
P/B
9.75
EV/EBITDA
-0.29
RETURN ON EQUITY
-195.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.6%
FLOAT SHARES
29,821,096
AVG. DAILY VOLUME (30D)
357,257
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Jasper Therapeutics stock
What does Jasper Therapeutics do?
Jasper Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jeetinder Singh Mahal, the company employs around 22 people.
The IPO was on 10/01/2020; the stock trades on NASDAQ under the ticker JSPR.
What do analysts say about Jasper Therapeutics stock?
13 analysts rate the stock, the consensus is Buy (as of 15/05/2026).
The average price target is US$2.50, ranging from US$2.00 to US$3.00, with a median of US$2.50.
This is an external assessment, not a statement by Market Jury.
When does Jasper Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly -34% stronger than usual.
Does Jasper Therapeutics pay a dividend?
No, Jasper Therapeutics currently does not pay a dividend.
Which stocks are comparable to Jasper Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Jasper Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Jasper Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.